Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Similar Posts
Spot bitcoin ETFs begin trading today: Here’s what investors can expect
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Anthony Pompliano, Pomp Investment founder and partner, joins ‘Squawk Box’ to discuss the SEC’s approval of spot bitcoin ETFs, what it means for investors and the crypto community at large, and more. 09:47 Thu, Jan 11 20248:00 AM EST
A Suze retrospective
Classic clips from 13 years of The Suze Orman Show.
Seven things you never knew about Scrabble
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email In honor of Scrabble Day, CNBC has compiled the most important numbers on the world-popular board game. Did you known approximately 150 million sets have been sold worldwide? 00:00 Mon, Apr 13 20158:00 AM EDT
Porsche unveils 2017 911 Turbo
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Detlev Von Platen, Porsche Cars North America talks to CNBC’s Phil LeBeau about the luxury automaker’s newest sports model. 02:17 Mon, Jan 11 20166:30 AM EST
Watch CNBC’s full interview with Ritholtz’s Josh Brown and SoFi’s Liz Young
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Josh Brown, Ritholtz Wealth Management CEO and Liz Young, SoFi, join ‘Closing Bell’ to discuss the Nasdaq’s momentum, big bank earnings expectations and their market outlook.
Financial impact from Boeing’s Max-9 blowout is still limited, says Morningstar’s Nicolas Owens
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Nicolas Owens, Morningstar, joins ‘Fast Money’ to explain why he believes the financial impact of Boeing’s Max-9 incident won’t be a long term concern for the stock.
